• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FOXK2 regulates PFKFB3 in promoting glycolysis and tumorigenesis in multiple myeloma
Leuk Res. 2023 Jun 17;132:107343. doi: 10.1016/j.leukres.2023.107343. Online ahead of print.ABSTRACTForkhead box K2 (FOXK2) is a transcription factor involved in regulating the pathophysiological processes in many types of cancers. Functioning as either an oncogene or tumor suppressor, FOXK2 is involved in cell proliferation, metastasis, DNA damage, metabolism, and autophagy. However, the functions of FOXK2 in multiple myeloma (MM) are still unexplored. Here we show that FOXK2 silencing by small interfering RNA (siRNA) prevented the expression of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) via dephosphor...
Source: Cell Research - June 25, 2023 Category: Cytology Authors: Xinling Liu Na Tang Yong Liu Jieting Fu Yao Zhao Haihua Wang Haiying Wang Zhenbo Hu Source Type: research

A novel protein encoded by circHNRNPU promotes multiple myeloma progression by regulating the bone marrow microenvironment and alternative splicing
CONCLUSION: Our findings demonstrate that circHNRNPU_603aa is a promising diagnostic and therapeutic marker in both MM cells and BM niche.PMID:35260179 | DOI:10.1186/s13046-022-02276-7
Source: Cell Research - March 9, 2022 Category: Cytology Authors: Xiaozhu Tang Zhendong Deng Pinggang Ding Wanting Qiang Yue Lu Shengyao Gao Ye Hu Ye Yang Juan Du Chunyan Gu Source Type: research

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
CONCLUSIONS: This study identifies PYCR1 as a novel target in bortezomib-based combination therapies for MM.PMID:35105345 | DOI:10.1186/s13046-022-02250-3
Source: Cell Research - February 2, 2022 Category: Cytology Authors: Inge Oudaert Hatice Satilmis Philip Vlummens Wouter De Brouwer Anke Maes Dirk Hose Elke De Bruyne Bart Ghesqui ère Karin Vanderkerken Kim De Veirman Eline Menu Source Type: research